CINPHA.ST Cinclus Pharma

Healthcare Drug Manufacturers - Specialty & Generic Stockholm Exchange
12.08 SEK
Close of Nov 7, 2026
10.48 19.64
Market cap
SEK 562M
P/E
-
P/B
2.64x
ROE
-165.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CINPHA.ST undervalued?

Graham number

The Graham number of Cinclus Pharma cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cinclus Pharma fundamental analysis

No fundamental analysis for Cinclus Pharma yet.

Cinclus Pharma stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cinclus Pharma

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylor…

Full company profile